跳至主要内容
临床试验/ACTRN12617000726358
ACTRN12617000726358尚未招募1 期

Efficacy of iodine solution delivered through a delivery device for eradication of persistent HPV infection following treatment for high-grade cervical intraepithelial neoplasia.

Jenny McClloskey0 个研究点目标入组 60 人开始时间: 2017年5月18日最近更新:
适应症

试验速览

阶段
1 期
状态
尚未招募
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
25 Years 至 o limit(—)
性别
Female

入选标准

  • Women previously treated for CIN 2 - 3 with persistent HrHPV post treatment.
  • Women Digene Hybrid Capture 2 positive (or other HPV test)
  • Women 25 year or over

排除标准

  • Under the age of 25
  • Pregnancy, or planning to become pregnant
  • Current thyroid disease
  • Past history of thyroid disease
  • Family history of thyroid disease
  • History of allergy to iodine
  • History of allergy to rubber
  • History of anaphylaxis
  • Untreated gonorrhoea, or chlamydia
  • Current CIN 2 – 3 on cytology or biopsy
  • HIV infection or other immune deficiency
  • Impaired renal function
  • Autoimmune disorders
  • Systemic or topical steroid therapy
  • IUCD in situ

研究者

发起方
Jenny McClloskey

相似试验